



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 17TH OCTOBER 2018
AT 12.30pm

IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chair)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mr A Zakaria (AZ)	Pharmacist LCFT (representing Mrs C Harding)

IN ATTENDANCE:

Mrs V Simpson (VS), Homecare & Rheumatology Pharmacist (for item 2018/149)
Mr C Gardner (CG), Consultant Paediatrician (for item 2018/153 & 2018/154)

2018/143: APOLOGIES:

Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mrs C Harding (CH)	Pharmacist LCFT

2018/144: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/145: MINUTES OF SEPTEMBER MEETING:

Accepted as a correct record.

2018/146: MATTERS ARISING:

2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines –
LR/JV/CD to suggest updated wording to clarify point 3 on page 7 in the transition to
adult services section. VG then to follow up with specialist.

2018/073: Rifaxamin – Guidelines for Prescribing – Response received with information on recurrent episodes and course length. JV/LR to amend document with information and ask gastro pharmacist to review amended document against NICE.

2018/133: Formulary Updates – Adrenaline Auto injectors – Hot Topic circulated. More information has been received from NHS England and this has also been circulated.

2018/135: Vitamin D Supplies for Paediatrics – Hot Topic in preparation

2018/147: NEW PRODUCT REQUEST – CIMETIDINE (UNLICENSED INDICATION)

Cimetidine requested by Mr J Shanks, Consultant Obs & Gynae, for bladder pain syndrome. This unlicensed indication is included in the RCOG Green Top Guideline for consideration by a specialist when first line conservative treatments have failed.

ELMMB agreed its use as a restricted drug (not included on formulary) by specialists in line with RCOG guidelines.

Resolved: Cimetidine for bladder pain syndrome agreed for specialist use only.

2018/148: LMMG CONSULTATIONS (for Nov LMMG)

None received

2018/149: LMMG RECOMMENDATIONS (from Sept LMMG)

Osvaren® change from Red to Amber traffic light recommended – accepted for use in ELHE.
Traffic Light: Amber

Rituximab for Autoimmune Haemolytic Anaemia Recommendation - accepted as written for use in ELHE.
Traffic light: Red – CCG commissioned

Rituximab for Idiopathic Thrombocytopenia Recommendation - accepted as written for use in ELHE.
Traffic light: Red - CCG commissioned

Anti-hyperglycaemic Guideline - updated – concern expressed that the additional statement regarding GLP-1s and insulin will not achieve what is needed. CCG's would like to see a positive statement with stopping criteria for GLP-1s if patients do not meet NICE criteria for continuation. LR to send comments to LMMG and request a position statement. If LMMG do not review then to take to Health Economy Diabetes Health Improvement Board.

Action: LR to send comments to LMMG and request position statement.

Ulipristal Guidance – the MHRA have updated the guidance on ulipristal with new restrictions on use and requirements for liver function monitoring. It was agreed to change traffic light to Red for use in line with MHRA guidance and LMMG.

DMARD Shared Care Guideline – the shared care guideline has been updated with the form as an electronic document.

The trust has developed a pathway for rheumatology and a spreadsheet to monitor when shared care letters are sent out and replies received. The trust is concerned about what would happen if specialist teams did not receive confirmation by the GP to continue prescribing. Rheumatology will use the shared care form as a basis but will include the relevant information in an electronic letter with a link to the shared care documents. ELMMB suggested that the wording on the top of the letter should state that 'it will be assumed the GP will take over prescribing. If GP is unwilling to take on prescribing, a response must be sent to the specialist team outlining the reason for refusal'. A template letter will be sent out for comments when prepared.

Action: Trust to circulate sample template letter for comments

EXTRA ITEM: ADALIMUMAB RMOC Briefing

The North RMOC has issued a briefing document outlining the position on adalimumab biosimilar preparations. The briefing provides an update for provider trusts, clinicians and commissioners. Implementing best value biological medicines enables the NHS to continue to improve patient care and provide new treatments now and into the future. It is a key element of NHS England's Medicines Value Programme. Biosimilar versions of the original biological medicine adalimumab are due to be introduced in the NHS as part of a formal framework agreement from 1 December 2018 after the patent for Humira® expires in October 2018. The briefing highlights key issues relating to: Procurement; System incentives; Patient group engagement; Clinical engagement; Product updates; Citrate content; Paediatric prescribing; Homecare implications and clinical questions.

Resolved: RMOC Briefing on Adalimumab acknowledged

2018/150: FORMULARY UPDATES

Chlordiazepoxide – change from Amber to Red traffic light. After discussion with LSC medicines leads it was suggested that treatment should be started and maintained by specialist services.

Traffic Light: Red

Trimovate cream® – remove from formulary as there are difficulties obtaining supplies and alternative preparations are available in formulary.

Comment: GP's are being requested by district nurses to prescribe Trimovate for hyper-granulation. Discuss with tissue viability nurse.

Resolved: Formulary to be updated as above

2018/151: ELHT: PROCEDURE FOR THE ADMINISTRATION OF SUBCUTANEOUS PRN MEDICATION USING A PRESCRIBED RANGE OF DOSES FOR SYMPTOMS IN THE LAST DAYS OF LIFE

The procedure, was acknowledged at ELMMB in March, and has been approved internally within the Trust. The chart that supports the guidance has been recently developed to complement the procedure. Comments received: Overall the layout is helpful and easy to use however a number of comments need to be considered and included within the document. LR/SJ to feedback comments to CW.

Action: CW to feedback comments to specialist.

2018/152: NHSE: GENDER IDENTITY DEVELOPMENT SERVICE FOR CHILDREN AND ADOLESCENTS

Policy from NHSE to upload to the website as a useful resource.

Resolved: NHSE Gender Identity Development Service for Children and Adolescents policy to be uploaded to website.

2018/153: CCG COMMISSIONING POLICY FOR THE PROVISION OF INSULIN PUMPS FOR PATIENTS WITH DIABETES MELLITUS

New policy for the commissioning of insulin pumps has been developed across LSC ICS and approved by the Joint Committee of CCGs in October 2018. Existing patients will need to be reviewed in accordance with NICE and local policy for continuation.

Resolved: CCG Commissioning Policy for Insulin Pumps acknowledged.

2018/154: CCG COMMISSIONING POLICY FOR THE PROVISION OF CONTINUOUS GLUCOSE MONITORING AND FLASH GLUCOSE MONITORING FOR PATIENTS WITH DIABETES MELLITUS

Policy for the commissioning of continuous glucose monitoring and flash glucose monitoring has been developed across LSC ICS and approved by the Joint Committee of CCGs in October 2018. Dr Chris Gardner updated the group on the policy and how it would be used and implemented within paediatrics.

It would be of particular benefit in children experiencing night time hypos. There was some concern over the wording in the policy that relates to '8 prick tests per day' which varies from the RMOC advice. Further concerns of the administrative burden associated with prescribing were raised alongside completion of the Blueteq forms. LR to discuss policy concerns re number of tests with CCG medicines leads and CSU team.

Prescribing and supply issues to be discussed with pharmacy.

Resolved: CCG Commissioning Policy for continuous and flash glucose monitoring acknowledged. Concerns with policy wording to be raised with CSU.

2018/155: NICE RECOMMENDATIONS (from Sept)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [TA540]

- is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin.

Traffic Light: BLACK

- is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant.

Approved in line with NICE.

Traffic Light: RED

NHS England Cancer Drug Fund

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [TA541] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

STANDING ITEMS

2018/156: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Sept 2018

Minutes acknowledged

2018/157: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Aug 2018

Minutes acknowledged

Availability of Medicines

NF noted that we are all facing challenges with supply of medicines. It is becoming more common to have shortages of medicines that are difficult to resolve.

DATE OF NEXT MEETING – Wednesday 21st November 2018 12.30pm, Seminar Room 2, Learning & Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 17TH OCTOBER 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2018/052	LMMG Recommendations (from Feb LMMG) Melatonin guidelines – suggest wording to clarify transitional information. Follow up with specialists	LR/JV/CD VG	Nov 18 Nov 18
2018/073	Rifaxamin – Guidelines for Prescribing –amend document with comments. Gastro pharmacist review against NICE	LR/JV VG	Nov 18 Nov 18
2018/135	VITAMIN D SUPPLIES FOR PAEDIATRICS To produce & circulate HOT Topic	LR	Oct 2018
2018/149	LMMG Recommendations (from Sept LMMG) Anti-hyperglycaemic Guideline – comments to LMMG and request position statement	LR	Nov 18
2018/149	LMMG Recommendations (from Sept LMMG) DMARD Shared Care Guideline – template letter for shared care for rheumatology to be prepared and sent out for comment.	VS	Nov 18
2018/151	ELHT: Procedure For The Administration Of Subcutaneous Prn Medication Using A Prescribed Range Of Doses For Symptoms In The Last Days Of Life – comments on chart to be fed back.	CW	Nov 18
2018/154	CCG Commissioning Policy For The Provision Of Continuous Glucose Monitoring And Flash Glucose Monitoring For Patients With Diabetes Mellitus – comments on wording to be raised with MM Leads and CSU.	LR	Nov 18